The use of hypolipidemic agents in patients with hyperuricemia on the background of type 2 diabetes mellitus and atherosclerosis

Diabetes mellitus (DM) is one of the most common pathologies today. According to the Federal Register of Diabetes Mellitus, the number of patients increases by about 5% every year. As a rule, the medical history is complicated by the presence of other concomitant pathologies. And this applies not only to cardiovascular diseases, but also to lipid metabolism disorders (dyslipidemia, obesity, atherosclerosis), uric acid metabolism and excretion (hyperuricemia, gout). There was a clear correlation between complications of diabetes and atherosclerosis due to an increase in uric acid levels in blood plasma. This increase can occur for several reasons. Hereditary predisposition, consumption of foods with a high content of purine compounds and further violation of their excretion, adherence to strict diets, intense physical activity. Patients, as a rule, experience severe unbearable joint pain, swelling and redness of the skin at the site of the lesion. It should be noted that asymptomatic hyperuricemia appeared not so long ago, in which uric acid levels reach critical values without obvious clinical symptoms. Hyperuricemia is another aggravating factor for patients with type 2 diabetes. It is important that such patients are characterized by polyprogmasia. And here, special attention should be paid to the interaction of drugs and the identification of additional positive pharmacological effects on concomitant pathologies. It is known that drugs from the group of statins have multiple effects. That is why the study of the full range of pharmacological effects and their possible application in practical medicine remains one of the main tasks of pharmacotherapy.

1. Polyakova EA, Konradi AO, Baranova EI, Galyavich AS, Ionin VA, Ostroumova OD et al. Current approaches to the treatment of hypertensive patients in view of modern guidelines. Cardiovascular Therapy and Prevention (Russian Federation). 2024;23(8):4140. (In Russ.) https://doi.org/10.15829/1728-8800-2024-4140.

2. Lin GL, Lin HC, Lin HL, Keller JJ, Wang LH. Association between statin use and the risk of gout in patients with hyperlipidemia: A population-based cohort study. Front Pharmacol. 2023;14:1096999. https://doi.org/10.3389/fphar.2023.1096999.

3. Shostak NA, Pravdyuk NG, Loginova TK, Lazarenko GN. Hyperuricemia, gout and comorbidity. The Сlinician. 2022;16(3):58–64. (In Russ.) https://doi.org/10.17650/1818-8338-2022-16-3-K648.

4. Voronko IA. Hyperuricemia is more than gout. Meditsinskie Novosti. 2022;(7):39–41. (In Russ.) Available at: https://www.mednovosti.by/journal.aspx?article=9682.

5. Amirov NB, Naumova AYa, Fatykhov RG, Amirova RN. Hyperuricemia: clinical consequences, cardiovascular risk, modern approach to therapy. Bulletin of Contemporary Clinical Medicine. 2022;15(1):95–106. (In Russ.) https://doi.org/10.20969/VSKM.2022.15(1).95-106.

6. Kutishenko NP, Martsevich SYu, Zagrebelnyy AV, Lukina YuV, Voronina VP, Dmitrieva N.A et al. Detection and Treatment of Hyperuricemia in Clinical Practice (According to the PROFILE Outpatient Registry). Rational Pharmacotherapy in Cardiology. 2022;18(4):449–454. (In Russ.) https://doi.org/10.20996/1819-6446-2022-08-12.

7. Kunitskaya NA, Ariev AL, Nemirovskiy VS. The role of uric acid in the development of cardiovascular diseases: from molecular mechanisms to clinical

8. manifestations. Vrach. 2022;33(6):5–12. (In Russ.) https://doi.org/10.29296/25877305-2022-06-01.

9. Shabalin VV, Grinstein YuI, Ruf RR, Samsonov NS. Asymptomatic hyperuricemia: obvious, controversial, hypothetical. Profilakticheskaya Meditsina. 2023;26(7):103–109. (In Russ.) https://doi.org/10.17116/profmed202326071103.

10. Kobalava ZhD, Troitskaya EA. Asymptomatic Hyperuricemia and Risk of Cardiovascular and Renal Diseases. Kardiologiya. 2020;60(10):113–121. (In Russ.) https://doi.org/10.18087/cardio.2020.10.n1153.

11. A patient with hyperuricemia: the algorithm of the doctor’s actions and regulatory documents. Pharmacology & Pharmacotherapy. 2021;(1):35–37. (In Russ.) Available at: https://elibrary.ru/vmhwzd.

12. Sivordova LE, Polyakova YuV, Papichev EV, Akhverdyan YuR, Zavodovsky BV. Clinical significance of colchicine in pharmacotherapy of cardiovascular pathology in patients with hyperuricemia in rheumatic diseases. Meditsinskiy Sovet. 2021;(19):188–199. (In Russ.) https://doi.org/10.21518/2079-701X-2021-19-188-199.

13. Belyaeva IB, Mazurov VI, Petrova MS, Bashkinov RA, Fonturenko AYu. International and Russian recommendations for urate-lowering therapy in comorbid patients with hyperuricemia or gout. Effective Pharmacotherapy. 2021;17(7):32–38. (In Russ.) Available at: https://elibrary.ru/azngga.

14. Chazova IE, Zhernakova YuV, Kislyak OA, Podzolkov VI, Oshchepkova EV, Mironova OYu, Blinova NV. Consensus on patients with hyperuricemia and high cardiovascular risk treatment: 2022. Systemic Hypertension. 2022;19(1):5–22. (In Russ.) https://doi.org/10.38109/2075-082X-2022-1-5-22.

15. Popov SV, Sturov NV. Comparative studies of nephroprotection effectiveness during antihyperuricaemic treatment in patients with chronic kidney disease. Trudnyj Pacient. 2019;17(10):48–51. (In Russ.) Available at: https://elibrary.ru/hwnyqi.

16. Zhang Z, Xu MH, Wei FJ, Shang LN. Clinical study of different doses of atorvastatin combined with febuxostat in patients with gout and carotid atherosclerosis. Pak J Med Sci. 2020;36(6):1334–1338. https://doi.org/10.12669/pjms.36.6.2945.

17. Alekberova ZS, Nasonov EL. Prospects for using colchicine in medicine: new evidence. Rheumatology Science and Practice. 2020;58(2):183–190. (In Russ.) Available at: https://rsp.mediar-press.net/rsp/article/view/2876.

18. Sumpter NA, Saag KG, Reynolds RJ, Merriman TR. Comorbidities in gout and hyperuricemia: causality or epiphenomena? Curr Opin Rheumatol. 2020;32(2):126–133. https://doi.org/10.1097/BOR.0000000000000691.

19. Kimura Y, Tsukui D, Kono H. Uric Acid in Inflammation and the Pathogenesis of Atherosclerosis. Int J Mol Sci. 2021;22(22):12394. https://doi.org/10.3390/ijms222212394.

20. Lee TS, Lu TM, Chen CH, Guo BC, Hsu CP. Hyperuricemia induces endothelial dysfunction and accelerates atherosclerosis by disturbing the asymmetric dimethylarginine/dimethylarginine dimethylaminotransferase 2 pathway. Redox Biol. 2021;46:102108. https://doi.org/10.1016/j.redox.2021.102108.

21. He B, Nie Q, Wang F, Wang X, Zhou Y, Wang C et al. Hyperuricemia promotes the progression of atherosclerosis by activating endothelial cell pyroptosis via the ROS/NLRP3 pathway. J Cell Physiol. 2023;238(8):1808–1822. https://doi.org/10.1002/jcp.31038.

22. Nishizawa H, Maeda N, Shimomura I. Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease. Hypertens Res. 2022;45(4):635–640. https://doi.org/10.1038/s41440-021-00840-w.

23. Rafiullah M, Siddiqui K, Al-Rubeaan K. Association between serum uric acid levels and metabolic markers in patients with type 2 diabetes from a community with high diabetes prevalence. Int J Clin Pract. 2020;74(4):e13466. https://doi.org/10.1111/ijcp.13466.

24. Siniscalchi C, Basaglia M, Riva M, Meschi M, Meschi T, Castaldo G, Di Micco P. Statins Effects on Blood Clotting: A Review. Cells. 2023;12(23):2719. https://doi.org/10.3390/cells12232719.

25. Madyanov IV. Relationships with type 2 diabetes mellitus of the basic parameters of urine acid metabolism with indicators of insulin resistance. Bulletin of Science and Practice. 2020;6(1):122–128. https://doi.org/10.33619/2414-2948/50/13.

26. Madyanov IV. Hyperuricemia and diabetes mellitus. RMJ. Medical Review. 2019;3(1):20–24. (In Russ.) Available at: https://www.rmj.ru/articles/endokrinologiya/Giperurikemiya_i_saharnyy_diabet/.

27. Sorokina YuA, Lovtsova LV, Urakov AL, Zanozina OV. Genetic Polymorphism in Patients with Newly Diagnosed Type 2 Diabetes Mellitus. Sovremennye Tehnologii v Medicine. 2019;11(2):57–62. (In Russ.) https://doi.org/10.17691/stm2019.11.2.08.

28. Занозина ОВ, Сорокина ЮА, Ловцова ЛВ, Ураков АЛ. Глиптины в инкретин-направленной фармакотерапии сахарного диабета: возможности и персонализация. Нижний Новгород: Ремедиум Приволжье; 2018. 112 с. Режим доступа: https://medialnn.ru/?id=17467&download=1.

29. Urakov AL, Sorokina YA, Lovtsova LV. 2022. “Long COVID” Molecular Genetic Markers in Patients with Type 2 Diabetes Mellitus. Med Res Arch. 2022;10(7). https://doi.org/10.18103/mra.v10i7.2933.

30. Ruda MМ, Karpov YuA. Hyperuricemia and cardiovascular risk: modern view on the problem. Atmosphere. Cardiology News. 2020;(1):3–14. (In Russ.) Available at: https://www.elibrary.ru/bmqqan.

31. McCormick N, O’Connor MJ, Yokose C, Merriman TR, Mount DB, Leong A, Choi HK. Assessing the Causal Relationships Between Insulin Resistance and Hyperuricemia and Gout Using Bidirectional Mendelian Randomization. Arthritis Rheumatol.2021;73(11):2096–2104. https://doi.org/10.1002/art.41779.

32. Izmozherova NV, Popov AA, Kuryndina AA, Gavrilova EI, Shambatov MA, Bakhtin VM. Polymorbidity and Polypragmasia in High and Very High Cardiovascular Risk Patients. Rational Pharmacotherapy in Cardiology. 2022;18(1):20–26. (In Russ.) https://doi.org/10.20996/1819-6446-2022-02-09.

33. Lebedev PA, Volova LT, Osina NK, Paranina EV. NLRP3 Inflammasome – a new universal target of asymptomatic hyperuricemia and gout management. Rational Pharmacotherapy in Cardiology. 2024;20(3):331–339. (In Russ.) https://doi.org/10.20996/1819-6446-2024-3018.

34. Urakov AL, Sorokina YuA, Lovtsova LV, Makarova EV, Zanozina OV. Novel Predictors for Personalized Pharmacotherapy in Type 2 Diabetes and COPD. Adv Biores. 2021;12(2):241–245. Available at: https://soeagra.com/abr/abrmarch2021/35.pdf.

35. Musaeva NZ, Oshchepkova EV, Aksenova AV, Gurtsiev TM, Chazova IE. Connection between uric acid and cardiovascular risk factors in hypertensive patients. Systemic Hypertension. 2023;20(3):19–25. (In Russ.) https://doi.org/10.38109/2075-082X-2023-3-19-25.

36. Prado Y, Aravena D, Llancalahuen FM, Aravena C, Eltit F, Echeverría C et al. Statins and Hemostasis: Therapeutic Potential Based on Clinical Evidence. Adv Exp Med Biol. 2023;1408:25–47. https://doi.org/10.1007/978-3-031-26163-3_2.

37. Velikaya OV, Nedomolkina SA, Nedomolkin SV. Evaluation of the effect of statins on cytokine and endothelial imbalances in patients with chronic obstructive pulmonary disease and diabetes mellitus. Lechaschi Vrach. 2020;(3):22–25. (In Russ.) https://doi.org/10.26295/OS.2020.67.66.003.

38. Abrahami D, Hudson M, Suissa S. Statins and lower mortality in rheumatic diseases: An effect of immortal time bias? Semin Arthritis Rheum. 2021;51(1):211–218. https://doi.org/10.1016/j.semarthrit.2020.11.010.

39. Okyay K. Pleiotropic effects of statins: New evidences. Turk Kardiyol Dern Ars. 2021;49(7):533–535. https://doi.org/10.5543/tkda.2021.21211.

40. Akbari A, Razmi M, Rafiee M, Watts GF, Sahebkar A. The Effect of Statin Therapy on Serum Uric Acid Levels: A Systematic Review and Metaanalysis. Curr Med Chem. 2024;31(13):1726–1739. https://doi.org/10.2174/0929867330666230207124516.

41. Kim M, Kim SE, Lee SM, An WS. Effect of pitavastatin on erythrocyte membrane fatty acid content in patients with chronic kidney disease: two-arm parallel randomized controlled trial. J Yeungnam Med Sci. 2024;41(3):188–195. https://doi.org/10.12701/jyms.2024.00094.